Saha Biplab K, Chong Woon H, Saha Santu, Aiman Alexis, Bonnier Alyssa
Department of Pulmonary and Critical Care Medicine, Ozarks Medical Center, 1100 Kentucky Avenue, West Plains, Missouri, MO, 65775, USA.
Department of Pulmonary and Critical Care Medicine, Albany Medical Center, Albany, NY, USA.
Lung. 2022 Apr;200(2):205-215. doi: 10.1007/s00408-022-00523-4. Epub 2022 Mar 10.
Idiopathic pulmonary hemosiderosis (IPH) is a rare disease that causes diffuse alveolar hemorrhage (DAH). The latest data suggests an immunologic origin of IPH, and a new name, immune mediated pulmonary hemosiderosis (ImPH), has been proposed. However, the exact immunologic mechanism has remained elusive for nearly eight decades despite extensive research, including detailed histopathologic analysis. Although several hypotheses have been proposed to describe the pathobiology of IPH, none of them explain the clinical and histopathologic findings conclusively. In this manuscript, we have presented a new hypothesis for the pathogenesis of DAH in IPH. We hypothesize that DAH in IPH is not immunocomplex mediated but due to histamine, eosinophilic cationic protein (ECP), and possibly vascular endothelial growth factor (VEGF). These bioactive proteins induce endothelial and alveolar epithelial damage, leading to the peri-capillary and intraalveolar escape of RBCs. The deformability of the RBC likely also plays a role. The supranormal secretion of histamine, ECP and VEGF occurs in genetically predisposed individuals with an aberrant immunologic response. The histamine is released from the basophils and possibly the mast cells in response to cytokines secreted by activated lymphocytes. The lymphocyte activation occurs after exposure to a known (gluten) or unknown antigen. The same lymphocyte-derived cytokines also induce eosinophilic degranulation of ECP and VEGF in the pulmonary circulation. We believe that our hypothesis unifies the observed clinical variabilities and histopathologic findings in IPH, and we hope that would promote future research in the field of IPH.
特发性肺含铁血黄素沉着症(IPH)是一种导致弥漫性肺泡出血(DAH)的罕见疾病。最新数据表明IPH起源于免疫因素,因此有人提出了一个新名称,即免疫介导的肺含铁血黄素沉着症(ImPH)。然而,尽管进行了广泛研究,包括详细的组织病理学分析,但近八十年来,确切的免疫机制一直难以捉摸。虽然已经提出了几种假说来描述IPH的病理生物学,但没有一种能够确凿地解释临床和组织病理学发现。在本手稿中,我们提出了一种关于IPH中DAH发病机制的新假说。我们假设IPH中的DAH不是由免疫复合物介导的,而是由组胺、嗜酸性阳离子蛋白(ECP)以及可能的血管内皮生长因子(VEGF)引起的。这些生物活性蛋白会导致内皮细胞和肺泡上皮细胞损伤,从而使红细胞在毛细血管周围和肺泡内逸出。红细胞的可变形性可能也起了作用。组胺、ECP和VEGF的超常分泌发生在具有异常免疫反应的遗传易感个体中。组胺是由嗜碱性粒细胞以及可能的肥大细胞响应活化淋巴细胞分泌的细胞因子而释放的。淋巴细胞活化发生在接触已知(麸质)或未知抗原之后。同样是这些淋巴细胞衍生的细胞因子,也会在肺循环中诱导ECP和VEGF的嗜酸性粒细胞脱颗粒。我们相信我们的假说统一了IPH中观察到的临床变异性和组织病理学发现,并且希望这将促进IPH领域的未来研究。